CERO News & Events

CERo Therapeutics announces a key clinical update from the Company's ongoing CertainT-1 trial focused on patients with acute myeloid leukemia. Following completion of the dose-limiting toxicity observation period for the first cohort, investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events reported to date. Expansion was seen with or without lymphodepletion. Investigators gave four rounds of CER-1236 cells to the second patient enrolled, with myelodysplastic syndrome that progressed to AML with an inv3 chromosome translocation. A 61-day platelet transfusion-free interval was observed after CER-1236 treatment, exceeding a commonly referenced 8-week benchmark cited in clinical studies in the context of platelet transfusion independence. Transfusion independence ended following a subsequent round of lymphodepleting chemotherapy plus CER-1236 treatment.

CERo Therapeutics announces recent advances to the CertainT-1 trial that is focused on patients with acute myeloid leukemia (AML). Following completion of the dose-limiting toxicity observation period for the first cohort, a total of 4e6 cells/kg of CER-1236 was delivered to the first patient of the second cohort. This patient received a dose level four times higher than that administered to patients in the first cohort and has completed the DLT observation period. In addition, the investigators provided a fourth additional dose to the second patient in the first cohort, who remains on study. "Enrollment and dosing are ongoing in our Phase 1 clinical trial of CER-1236. The first patient in the second cohort has received a higher cell dose, and safety monitoring is continuing. In addition, one patient in the first cohort has received an additional dose and remains on study. We are focused on the careful conduct of the dose-escalation phase and the systematic collection of safety data as the trial proceeds," said CERo CEO Chris Ehrlich.

CERo Therapeutics announces its shares will be available to trade on the OTCQB market under the ticker symbol CERO effective today, December 2, 2025 as of 8:00AM ET. No action is needed on the part of investors. In the meantime, CERo continues to evaluate additional options for up-list, including, but not limited to listing on a major exchange to optimize liquidity and investor accessibility.